Malignant Melanoma Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
S
Recruiting
  • Malignant Melanoma
  • Squamous Cell Carcinoma of Skin
  • Beverly Hills, California
  • +27 more
2022-04-07
Apr 7, 2022
L
Terminated
  • Malignant Melanoma
  • 8 HLA-A2-restricted peptides and Montanide ISA51
  • 8 HLA-A2-restricted peptides and CpG 7909
  • Brussels, Belgium
  • +1 more
2022-04-05
Apr 5, 2022
L
Recruiting
  • Malignant Melanoma
  • delolimogene mupadenorepvec
  • atezolizumab
  • Los Angeles, California
  • +2 more
2022-04-04
Apr 4, 2022
M
Recruiting
  • Malignant Melanoma
    • Boston, Massachusetts
      Massachusetts General Hospital
    2022-04-04
    Apr 4, 2022
    S
    Active, not recruiting
    • Malignant Melanoma
    • Peginterferon alfa-2b
    • +2 more
    • San Diego, California
    • +2 more
    2022-04-01
    Apr 1, 2022
    D
    Not yet recruiting
    • Malignant Melanoma
    • +4 more
    • (no location specified)
    2022-03-31
    Mar 31, 2022
    U
    Recruiting
    • Malignant Melanoma
    • UV1
    • +3 more
    • Phoenix, Arizona
    • +39 more
    2022-03-29
    Mar 29, 2022
    I
    Active, not recruiting
    • Malignant Melanoma
    • Tebentafusp (IMCgp100)
    • +2 more
    • Los Angeles, California
    • +23 more
    2022-03-16
    Mar 16, 2022
    A
    Completed
    • Malignant Melanoma
    • Philadelphia, Pennsylvania
      Abramson Cancer Center of the University of Pennsylvania
    2022-03-23
    Mar 23, 2022
    U
    Not yet recruiting
    • Malignant Melanoma
    • +2 more
    • Stereotaxic radiosurgery (SRS)
    • +3 more
    • Bobigny, France
    • +25 more
    2022-03-23
    Mar 23, 2022
    M
    Recruiting
    • Advanced Solid Tumor
    • +6 more
    • MGC018
    • lorigerlimab
    • Los Angeles, California
    • +2 more
    2022-03-14
    Mar 14, 2022
    T
    Terminated
    • Malignant Melanoma
    • +2 more
    • ImmuniCell®
    • Cardiff, United Kingdom
    • +6 more
    2022-03-08
    Mar 8, 2022
    A
    Completed
    • Malignant Melanoma
    • Aarhus, Denmark
      AUH
    2022-02-16
    Feb 16, 2022
    U
    Recruiting
    • Malignant Melanoma
    • Head and Neck Cancer
    • Aurora, Colorado
      University of Colorado Cancer Center
    2022-02-18
    Feb 18, 2022
    4
    Completed
    • Malignant Melanoma
    • 4SC-202 in combination with Pembrolizumab
    • Essen, Germany
    • +6 more
    2022-02-03
    Feb 3, 2022
    U
    Not yet recruiting
    • Malignant Melanoma
    • Oral Decitabine/Cedazuridine (DEC-C) in Combination with Nivolumab
    • Aurora, Colorado
      University of Colorado Hospital
    2022-02-01
    Feb 1, 2022
    Y
    Not yet recruiting
    • SCLC
    • +2 more
    • GD2-SADA:177Lu-DOTA Complex
    • (no location specified)
    2022-01-05
    Jan 5, 2022
    T
    Active, not recruiting
    • Non-Small Cell Lung Cancer
    • +5 more
    • Houston, Texas
      Houston Methodist Cancer Center
    2021-12-28
    Dec 28, 2021
    R
    Recruiting
    • Solid Tumor
    • +15 more
    • RAPA-201 Rapamycin Resistant T Cells
    • Chemotherapy Prior to RAPA-201 Therapy
    • Hackensack, New Jersey
      Hackensack University Medical Center
    2021-12-23
    Dec 23, 2021
    P
    Completed
    • Malignant Melanoma
    • Nivolumab + Placebo
    • +2 more
    • Berlin, Germany
    • +19 more
    2021-12-10
    Dec 10, 2021
    H
    Completed
    • Malignant Melanoma
    • patient with melanoma pre transplantation
    • Lyon, Rhone, France
      service de dermatologie - hopital Edouard Herriot
    2021-12-09
    Dec 9, 2021